Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility
Project Number: CORDIS-106699
Project web address: Follow on CORDIS
Organization: Institut National De La Sante Et De La Recherche Medicale, France, Paris
Collaborators: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Universiteit Twente, NL
Assistance Publique - Hopitaux De Paris, FR
Syddansk Universitet, DK
Medizinische Universitat Graz, AT
Bracco Imaging S.P.A, IT
Commissariat A L'Energie Atomique Et Aux Energies Alternatives, FR
Inserm-Transfert Sa, FR
Semmelweis Egyetem, HU
Universitätsklinikum Erlangen, DE
Winzsoft (Israel) Ltd, IL
Edinethics Limited, GB
Nanopet Pharma Gmbh, DE
Europaische Stiftung Fur Klinische Nanomedizin, CH
Principal Investigators (PI): Catherine Clusel, FR
Ferdinand Damhuis, NL
Donald Bruce, GB
Dina Falkenreck, FR
Alix Pillot, FR
Arne Bækdal Hansen, DK
Gulseren Yalvac, NL
Nadine Stolz, DE
Antoine Dupont, FR
Beat Löffler, CH
Karin Heuchemer, DE
Vilmos Ivády, HU
Giusy Galgano, IT
Bianca Grunert, DE
Ingrid Reinprecht, AT
Avner Levy, IL
 
Project Description:
NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands. Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners from academia, a European association, SMEs and a large pharmaceutical company. NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development.In NanoAthero, the nanocarriers carrying compounds to visualize thrombus or vulnerable plaques, or to deliver therapeutic agents should be suitable for proof-of-concept in patients. Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma. NanoAthero aims to propose nanosystems for thrombus imaging, stroke treatment and plaque stabilization in high-risk patients. Molecular imaging and therapeutic treatments in NanoAthero are based on feasible approaches.
 
Project Terms:
scientific research
Project Title: Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility
Project Number: CORDIS-106699
Project web address: Follow on CORDIS
Organization: Institut National De La Sante Et De La Recherche Medicale, France, Paris
Collaborators: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Universiteit Twente, NL
Assistance Publique - Hopitaux De Paris, FR
Syddansk Universitet, DK
Medizinische Universitat Graz, AT
Bracco Imaging S.P.A, IT
Commissariat A L'Energie Atomique Et Aux Energies Alternatives, FR
Inserm-Transfert Sa, FR
Semmelweis Egyetem, HU
Universitätsklinikum Erlangen, DE
Winzsoft (Israel) Ltd, IL
Edinethics Limited, GB
Nanopet Pharma Gmbh, DE
Europaische Stiftung Fur Klinische Nanomedizin, CH
Principal Investigators (PI): Catherine Clusel, FR
Ferdinand Damhuis, NL
Donald Bruce, GB
Dina Falkenreck, FR
Alix Pillot, FR
Arne Bækdal Hansen, DK
Gulseren Yalvac, NL
Nadine Stolz, DE
Antoine Dupont, FR
Beat Löffler, CH
Karin Heuchemer, DE
Vilmos Ivády, HU
Giusy Galgano, IT
Bianca Grunert, DE
Ingrid Reinprecht, AT
Avner Levy, IL
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology > Cardiovascular and cerebrovascular diseases > Diseases of arteries, arterioles and capillaries
 
Other Information:
Fiscal Year: 2013
Project Start Date: 1 February 2013
Project End Date: 31 January 2018
Project program: FP7-NMP
 
Project Funding Information:
Funding Mechanism: CP-IP - Large-scale integrating project
Year Funding Organization Total Funding, $
2013 European Research Council $14,122,007